Summary
Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P, 95% confidence interval, 15%–47%). Response was not significantly related to age, performance status, disease-free interval, dominant site of disease, number of sites of disease, or estrogen receptor status. The median duration of response was 5 months for patients attaining CR or PR and 4.6 months for patients with stable disease. The median survival for patients with CR or PR of 7.9 months was not better than for those with stable disease (8.0 months), but both groups had significantly longer survival than those with initial progression. Patients who received VAM after failing adjuvant CMF had a 53% response rate (8 of 15), as against a 14% response rate (3 of 21) in those failing CMF for advanced disease (P<0.05). In spite of this difference, the survival distributions for these two groups were not significantly different. Myelosuppression was moderate and no cardiac toxicity was seen. The addition of mitomycin to vincristine and doxorubicin in previously treated patients does not appear to improve the results obtained with vincristine and doxorubicin alone.
Similar content being viewed by others
References
Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J I:801
Crooke ST, Bradner WT (1976) Mitomycin C: a review. Cancer Treat Rev 3:121
De Lena M, Jirillo A, Brambilla C, Villa S (1980) Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy. Tumori 66:481
DeLena M, Jirillo S, Villa A, Volonterio A, Villani F, Brambilla C, Bonadonna G (1981) Preliminary results with adriamycin (A) plus mitomycin (M) combination in metastatic breast cancer. (Abstract) Proc AACR/ASCO 22:435
Frank W, Osterberg AE (1960) Mitomycin C (NSC-26980) — An evaluation of the Japanese reports. Cancer Chemother Rep 9:114
Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika (London) 52:203
Godfrey TE (1979) Mitomycin C in breast cancer. In: Carter SK, Crooke ST (eds) Mitomycin C. Current status and new developments. Academic Press, New York, pp 91–99
Hart RD, Perloff M, Holland JF (1981) One-day VATH (vinblastine, adriamycin, thioTEPA and halotestin) therapy for advanced breast cancer refractory to chemotherapy. Cancer 48:1522
Hayward JL, Carbone PP, Henson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39:1289
Hoogstraten B, Fabian C (1979) A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2:101
Hum GJ, Bodgon DL, Bateman JR (1974) Phase I–II evaluation of weekly Mitomycin C (NSC-26980) for patients with metastatic GI and breast malignancies. Oncology 30:236
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457
Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. IFI/Plenum, New York
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
Oster MW, Park Y, Gossard L (1981) Vincristine (V), Adriamycin (A), and Mitomycin (M) therapy for previously treated breast cancer. (Abstract) Proc AACR/ASCO 22:448
Wise GR, Kuhn IN, Godfrey TE (1976) Mitomycin C in large infrequent doses in breast cancer. Med Pediatr Oncol 2:55
Author information
Authors and Affiliations
Additional information
POA members participating in this study: W. R. Black, Salisbury, NC, R. A. Brodkin, Winston-Salem, NC, R. Caldwell, Bristol, TN, F. W. Green, Albemarle, NC, R. Harding, Rutherfordton, NC, J. P. Olmert, Charlotte, NC, M. L. Slatkoff, Winston-Salem, NC
Rights and permissions
About this article
Cite this article
Shipp, S.K., Muss, H.B., Westrick, M.A. et al. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). Cancer Chemother. Pharmacol. 11, 130–133 (1983). https://doi.org/10.1007/BF00254262
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254262